Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
AAPS PharmSciTech ; 21(5): 189, 2020 Jul 10.
Artigo em Inglês | MEDLINE | ID: mdl-32651739

RESUMO

The aim of this study was to investigate the influence of the production method and the polymeric carrier on the ability to generate and maintain the supersaturation of a poorly soluble drug in biorelevant medium. The amorphous solid dispersion of sulfamethoxazole, an antibacterial drug, was produced using two different polymers by spray-drying or hot melt extrusion methods. When Eudragit EPO was used, supersaturation was maintained up to 24 h for both techniques at all drug-polymer proportions. However, when Soluplus was employed in hot melt extrusion, a smaller amount of drug was dissolved when compared to the amorphous drug. The proportion of 3:7 drug-Eudragit EPO (w/w) produced by spray-drying presented a higher amount of drug dissolved in supersaturation studies and it was able to maintain the physical stability under different storage conditions throughout the 90-day evaluation. Supersaturation generation and system stability were found to be related to more effective chemical interaction between the polymer and the drug provided by the production method, as revealed by the 1D ROESY NMR experiment. Investigation of drug-polymer interaction is critical in supersaturating drug delivery systems to avoid crystallization of the drug and to predict the effectiveness of the system. Chemical compounds studied in this article: Sulfamethoxazole (PubChem CID: 4539) and Methacrylate copolymer - Eudragit EPO (PubChem CID: 65358).


Assuntos
Preparações Farmacêuticas/química , Polietilenoglicóis/química , Ácidos Polimetacrílicos/química , Polivinil/química , Cristalização , Dessecação , Portadores de Fármacos/química , Composição de Medicamentos/métodos , Interações Medicamentosas , Estabilidade de Medicamentos , Solubilidade
2.
Expert Rev Anti Infect Ther ; 17(10): 841-850, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31577912

RESUMO

Background: The drug supersaturation in the intestinal lumen for few hours could result in high bioavailability. The goal of this study was the development of a supersaturating drug delivery system containing sulfamethoxazole and trimethoprim at fixed dose combination (sulfamethoxazole:trimethoprim 5:1 w/w). Methods: The amorphous solid dispersions were formed at three different proportions containing 30, 50 and 70% of Eudragit EPO in the formulation. Results: The supersaturation state is formed by the amorphous drugs produced by spray drying technique, and the maintenance of this state is due to the chemical interactions between the drugs and the polymer selected, which was observed in the fluorescence interaction studies realized between the drugs and the polymer. The Formulation containing 70% of the polymer was able to produce and maintain the supersaturated state of both drugs for 24 h. Solid state characterization demonstrated the amorphization of the drugs in the solid dispersion and indicated the hydrogen bond formation responsible for the improvement in the apparent solubility. This formulation presented an improved antibacterial activity when compared to the combination of the drugs. Conclusion: For the first time, a supersaturating drug delivery system was developed to the complementary antibacterial drugs. This ternary formulation is a powerful alternative to improve oral absorption of recognized safety drugs, reducing the dose and consequently the antibiotic resistance emergence.


Assuntos
Antibacterianos/administração & dosagem , Sistemas de Liberação de Medicamentos , Combinação Trimetoprima e Sulfametoxazol/administração & dosagem , Administração Oral , Antibacterianos/química , Antibacterianos/farmacologia , Química Farmacêutica , Portadores de Fármacos/química , Combinação de Medicamentos , Humanos , Polímeros/química , Ácidos Polimetacrílicos/química , Solubilidade , Fatores de Tempo , Combinação Trimetoprima e Sulfametoxazol/química , Combinação Trimetoprima e Sulfametoxazol/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA